Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Change in Directorate

Pursuant to the requirements under Regulation 30 of the Listing Regulations, we wish to inform you that Mr. Vivek Chaand Sehgal (DIN - 00291126) has tendered his resignation as Independent Director of the Company with effect from 1st September 2021 . Mr. Sehgal has stated in his resignation letter that the resignation is purely because of his personal reasons and other pre-occupations only and confirmed that there is no other material reason for his resignation. The resignation of Mr. Sehgal effective from 1st September 2021 , is taken on record and accepted by the Board of Directors of the Company by way of a circular resolution passed today i.e. 3rd September 2021 . We request you to kindly take the same on record
03-09-2021
Bigul

Sun Pharma forays into healthy snacking segment

Launches nutrition bars under brand Revital
02-09-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
02-09-2021
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
02-09-2021
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Voting Results of 29th Annual General Meeting of the Company held on August 31, 2021 in accordance with Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer''s Report
01-09-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Disclosure Under Regulation 30

Please find enclosed disclosure under Regulation 30
01-09-2021
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Chairman Speech At The 29Th Annual General Meeting Held On 31 August 2021

Chairman Speech at the 29th Annual General Meeting held on 31 August 2021
31-08-2021

Sun Pharma gets exclusive right to commercialise Winlevi acne cream in US

Sun Pharma and specialty pharma firm Cassiopea SpA announced consummation of their exclusive licence and supply agreements for Winlevi cream used for treatment of acne vulgaris
31-08-2021
Next Page
Close

Let's Open Free Demat Account